245 related articles for article (PubMed ID: 31156428)
1. Monoaminergic System Modulation in Depression and Alzheimer's Disease: A New Standpoint?
Morgese MG; Trabace L
Front Pharmacol; 2019; 10():483. PubMed ID: 31156428
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Treatment of Depression in Alzheimer's Disease: A Challenging Task.
Cassano T; Calcagnini S; Carbone A; Bukke VN; Orkisz S; Villani R; Romano A; Avolio C; Gaetani S
Front Pharmacol; 2019; 10():1067. PubMed ID: 31611786
[TBL] [Abstract][Full Text] [Related]
3. Sub-chronic celecoxib prevents soluble beta amyloid-induced depressive-like behaviour in rats.
Morgese MG; Schiavone S; Bove M; Mhillaj E; Tucci P; Trabace L
J Affect Disord; 2018 Oct; 238():118-121. PubMed ID: 29879605
[TBL] [Abstract][Full Text] [Related]
4. N-3 PUFA diet enrichment prevents amyloid beta-induced depressive-like phenotype.
Morgese MG; Schiavone S; Mhillaj E; Bove M; Tucci P; Trabace L
Pharmacol Res; 2018 Mar; 129():526-534. PubMed ID: 29203442
[TBL] [Abstract][Full Text] [Related]
5. The Challenge of Antidepressant Therapeutics in Alzheimer's Disease.
Lozupone M; La Montagna M; D'Urso F; Piccininni C; Rinaldi A; Beghi M; Cornaggia CM; Sardone R; Solfrizzi V; Daniele A; Seripa D; Giannelli G; Bellomo A; Panza F
Adv Exp Med Biol; 2020; 1260():267-281. PubMed ID: 32304037
[TBL] [Abstract][Full Text] [Related]
6. Cross Talk Between Brain Innate Immunity and Serotonin Signaling Underlies Depressive-Like Behavior Induced by Alzheimer's Amyloid-β Oligomers in Mice.
Ledo JH; Azevedo EP; Beckman D; Ribeiro FC; Santos LE; Razolli DS; Kincheski GC; Melo HM; Bellio M; Teixeira AL; Velloso LA; Foguel D; De Felice FG; Ferreira ST
J Neurosci; 2016 Nov; 36(48):12106-12116. PubMed ID: 27903721
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of amyloid beta in stress response: Implication for depression and diabetes.
Morgese MG; Schiavone S; Trabace L
Eur J Pharmacol; 2017 Dec; 817():22-29. PubMed ID: 28844871
[TBL] [Abstract][Full Text] [Related]
8. Precision Medicine in Alzheimer's Disease: Investigating Comorbid Common Biological Substrates in the Rat Model of Amyloid Beta-Induced Toxicity.
Morgese MG; Bove M; Di Cesare Mannelli L; Schiavone S; Colia AL; Dimonte S; Mhillaj E; Sikora V; Tucci P; Ghelardini C; Trabace L
Front Pharmacol; 2021; 12():799561. PubMed ID: 35046821
[TBL] [Abstract][Full Text] [Related]
9. Microglial dysfunction connects depression and Alzheimer's disease.
Santos LE; Beckman D; Ferreira ST
Brain Behav Immun; 2016 Jul; 55():151-165. PubMed ID: 26612494
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant drugs for beta amyloid-induced depression: A new standpoint?
Schiavone S; Tucci P; Mhillaj E; Bove M; Trabace L; Morgese MG
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Aug; 78():114-122. PubMed ID: 28499898
[TBL] [Abstract][Full Text] [Related]
11. (-)-P7C3-S243 Protects a Rat Model of Alzheimer's Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia.
Voorhees JR; Remy MT; Cintrón-Pérez CJ; El Rassi E; Khan MZ; Dutca LM; Yin TC; McDaniel LN; Williams NS; Brat DJ; Pieper AA
Biol Psychiatry; 2018 Oct; 84(7):488-498. PubMed ID: 29246437
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
13. Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state?
Colaianna M; Tucci P; Zotti M; Morgese MG; Schiavone S; Govoni S; Cuomo V; Trabace L
Br J Pharmacol; 2010 Apr; 159(8):1704-15. PubMed ID: 20218978
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity.
Hock C; Golombowski S; Müller-Spahn F; Naser W; Beyreuther K; Mönning U; Schenk D; Vigo-Pelfrey C; Bush AM; Moir R; Tanzi RE; Growdon JH; Nitsch RM
Eur Neurol; 1998; 39(2):111-8. PubMed ID: 9520072
[TBL] [Abstract][Full Text] [Related]
15. (Dys)regulation of Synaptic Activity and Neurotransmitter Release by β-Amyloid: A Look Beyond Alzheimer's Disease Pathogenesis.
Fagiani F; Lanni C; Racchi M; Govoni S
Front Mol Neurosci; 2021; 14():635880. PubMed ID: 33716668
[TBL] [Abstract][Full Text] [Related]
16. Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer's disease.
Romano A; Pace L; Tempesta B; Lavecchia AM; Macheda T; Bedse G; Petrella A; Cifani C; Serviddio G; Vendemiale G; Gaetani S; Cassano T
Int J Neuropsychopharmacol; 2014 Oct; 18(4):. PubMed ID: 25609597
[TBL] [Abstract][Full Text] [Related]
17. Serotonin 6 receptor controls Alzheimer's disease and depression.
Yun HM; Park KR; Kim EC; Kim S; Hong JT
Oncotarget; 2015 Sep; 6(29):26716-28. PubMed ID: 26449188
[TBL] [Abstract][Full Text] [Related]
18. Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent βAPP mRNA Amplification. An Engine that Drives Alzheimer's Disease.
Volloch V; Olsen BR; Rits S
Ann Integr Mol Med; 2019; 1(1):61-74. PubMed ID: 31858090
[TBL] [Abstract][Full Text] [Related]
19. Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care.
Trillo L; Das D; Hsieh W; Medina B; Moghadam S; Lin B; Dang V; Sanchez MM; De Miguel Z; Ashford JW; Salehi A
Neurosci Biobehav Rev; 2013 Sep; 37(8):1363-79. PubMed ID: 23707776
[TBL] [Abstract][Full Text] [Related]
20. The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.
Vermeiren Y; Van Dam D; Aerts T; Engelborghs S; Martin JJ; De Deyn PP
Alzheimers Res Ther; 2015; 7(1):7. PubMed ID: 25717350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
